switching between glp-1 agonists ada Outcomes in RA-Experienced Patients to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study | Diabetes Therapy GLP1 agonists: current and future
Description
Oyama J, Murohara T, Kitakaze M, Ishizu T, Sato Y, Kitagawa K, et al
However, it is not yet confirmed if these medications pose the same risk to humans
A comprehensive meta-analysis of eight GLP-1 RA CVOTs revealed several critical findings: 14% reduction in major adverse cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke) [3] 13% reduction in cardiovascular death [3] 10% reduction in all-cause mortality [3] 11% reduction in hospitalization for heart failure [3] Post-hoc analyzes from LEADER and SUSTAIN-6 revealed that cardiovascular benefits extended across the spectrum of body mass index categories, indicating efficacy regardless of baseline weight [2]
How Your GLP-1 Diet Could Look Semaglutide vs Tirzepatide: Does Food Guidance Change
